Oncozenge AB (ST:ONCOZ) — Market Cap & Net Worth
Market Cap & Net Worth: Oncozenge AB (ONCOZ)
Oncozenge AB (ST:ONCOZ) has a market capitalization of $9.07 Million (Skr84.29 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27118 globally and #595 in its home market, demonstrating a 1.87% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncozenge AB's stock price Skr6.00 by its total outstanding shares 14048068 (14.05 Million). Analyse Oncozenge AB cash conversion from operations to see how efficiently the company converts income to cash.
Oncozenge AB Market Cap History: 2021 to 2026
Oncozenge AB's market capitalization history from 2021 to 2026. Data shows change from $17.48 Million to $9.07 Million (-12.78% CAGR).
Index Memberships
Oncozenge AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.06% | #168 of 281 |
Weight: Oncozenge AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oncozenge AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncozenge AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5669.24x
Oncozenge AB's market cap is 5669.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $4.67 Million | $3.00K | -$15.90 Million | 1557.15x | N/A |
| 2024 | $5.67 Million | $1.00K | -$8.69 Million | 5669.24x | N/A |
Competitor Companies of ONCOZ by Market Capitalization
Companies near Oncozenge AB in the global market cap rankings as of May 4, 2026.
Key companies related to Oncozenge AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oncozenge AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Oncozenge AB's market cap moved from $17.48 Million to $ 9.07 Million, with a yearly change of -12.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr9.07 Million | -11.24% |
| 2025 | Skr10.22 Million | +80.27% |
| 2024 | Skr5.67 Million | +21.36% |
| 2023 | Skr4.67 Million | -43.82% |
| 2022 | Skr8.31 Million | -52.42% |
| 2021 | Skr17.48 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Oncozenge AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.07 Million USD |
| MoneyControl | $9.07 Million USD |
| MarketWatch | $9.07 Million USD |
| marketcap.company | $9.07 Million USD |
| Reuters | $9.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.